Document is current

Article History

Received: 7 August 2023

Revised: 13 September 2023

Accepted: 24 September 2023

First Online: 6 October 2023

Declarations

:

: Andres Acosta was supported by NIH (NIH K23-DK114460), The Mayo Clinic Biobank, and Rhythm Pharmaceuticals for the genotyping studies. The Mayo Clinic Biobank is supported by the Mayo Clinic Center for Individualized Medicine. The funding source was not involved in the study design, in the collection, analysis, and interpretation of the data, in writing the report, or in the decision to submit the paper for publication. Andres Acosta holds equity in Phenomix Sciences Inc. Andres Acosta served as a consultant for Rhythm Pharmaceuticals, General Mills, Currax, Nestle, Amgen, Structure, and Boehringer Ingelheim. The rest of the authors declare no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study and all participants provided prior written authorization for research use of their medical records and biological samples, including their use for genotyping studies.

: None.

: The investigators will share deidentified data that underlies the results reported in this article after deidentification upon request by bona fide researchers who provide a methodologically appropriate proposal. Proposals should be directed to acosta.andres@mayo.edu. To gain access, data requestors will need to sign a data access agreement.